Through performing single-cell RNA and TCR sequencing of tumor and normal tissues and peripheral blood in patients with different types of cancer, Wu et al. found that patients who show clonal expansion of effector-like T cells in tumor tissue as well as in peripheral blood respond well to anti-PDL1 therapy [79]. This evidence concerns the gene CD274 and neoplasm.